SML3848
Y-320
≥98% (HPLC)
别名:
1-(4-Chlorophenyl)-N-[3-cyano-4-(4-morpholin-4-ylpiperidin-1-yl)phenyl]-5-methylpyrazole-4-carboxamide, 1-(4-Chlorophenyl)-N-[3-cyano-4-(4-morpholinopiperidin-1-yl)-phenyl]-5-methylpyrazole-4-carboxamide, 1-(4-Chlorophenyl)-N-[3-cyano-4-[4-(4-morpholinyl)-1-piperidinyl]phenyl]-5-methyl-1H-pyrazole-4-carboxamide, Y 320, Y320
登录 查看组织和合同定价。
选择规格
变更视图
关于此项目
Assay:
≥98% (HPLC)
Form:
powder
Quality Segment
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear (Warmed)
storage temp.
-10 to -25°C
SMILES string
N#CC1=CC(NC(C2=C(C)N(C3=CC=C(C=C3)Cl)N=C2)=O)=CC=C1N4CCC(CC4)N5CCOCC5
InChI
1S/C27H29ClN6O2/c1-19-25(18-30-34(19)24-5-2-21(28)3-6-24)27(35)31-22-4-7-26(20(16-22)17-29)33-10-8-23(9-11-33)32-12-14-36-15-13-32/h2-7,16,18,23H,8-15H2,1H3,(H,31,35)
InChI key
BWZNJVZTAWBIFG-UHFFFAOYSA-N
Biochem/physiol Actions
Orally active immune modulator that suppresses inflammatory cytokines production and blocks P-glycoprotein-mediated MDR in vitro and in vivo.
Y-320 is an orally active immune modulator that inhibits IL-15-stimulated (100 ng/mL) IL-17 production from T-cells (IC50 = 57.4 nM using human CD4 T-cells & hIL-15; IC50 = 25.7/52.4 nM using murine CD4/Th17 T-cells and mIL-15 plus 1 μ/mL mCXCL12 & 1 μg/mL anti-CD3ε mAb) and prevents type II collagen-induced arthritis (CIA) in mice in vivo (0.3 to 3 mg/kg via daily p.o.). Y-320 is a P-glycoprotein (P-gp) substrate and sensitizes MDR tumor cells to chemotherapy drugs in cultures (paclitaxel IC50 with/without 500 nM Y-320 = 0.21/1.15 μM/Bads-200, 16/153 nM/Bads-72 breast cancer cells) and in mice in vivo (0% vs. 78% tumor growth suppression by 15 mg/kg PTX without or with 15 mg/kg Y-320 i.v.).
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable